Compare GETY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | SLN |
|---|---|---|
| Founded | 1995 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 88 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.5M | 300.9M |
| IPO Year | 2022 | N/A |
| Metric | GETY | SLN |
|---|---|---|
| Price | $0.76 | $9.21 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $3.78 | ★ $42.60 |
| AVG Volume (30 Days) | ★ 11.7M | 648.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $926,244,000.00 | N/A |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $1.47 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $0.58 | $4.19 |
| 52 Week High | $3.21 | $11.06 |
| Indicator | GETY | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 55.24 |
| Support Level | $0.69 | $5.87 |
| Resistance Level | $0.95 | $11.06 |
| Average True Range (ATR) | 0.15 | 0.90 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 8.15 | 55.45 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.